Adalimumab biosimilar - Dong-A ST/Meiji Seika Pharma

Drug Profile

Adalimumab biosimilar - Dong-A ST/Meiji Seika Pharma

Alternative Names: DA-3113; DMB-3113

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical; Meiji Seika Pharma
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in Japan (Parenteral) (JapicCTI-163390)
  • 24 Jun 2016 Adalimumab biosimilar - Dong-A ST/Meiji Seika Pharma is available for licensing except in Japan as of 24 Jun 2015. http://www.donga-pharm.com
  • 19 Jun 2015 Adalimumab biosimilar - Dong-A ST/Meiji Seika Pharma is available for licensing except in Japan as of 19 Jun 2015. http://www.donga-pharm.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top